DEERFIELD BEACH, Fla., June 9, 2005 (PRIMEZONE) -- StockMarketNewsAlert.com is pleased to introduce our featured stock, Aethlon Medical, Inc. (OTCBB:AEMD), to the investment community. Aethlon Medical is new to Stock Market News Alert and AEMD has had several excellent news announcements out today. Investors should be watching this one closely.
AEMD announced today that Qualtran LLC, a contract research organization (CRO) managing biocompatibility studies and clinical trials for Aethlon in India, has advised the Company that the Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon's forthcoming Hepatitis-C (HCV) clinical trials in India. This could be great news for investors!
About Aethlon Medical
Aethlon Medical is pioneering the development of viral filtration devices to treat drug and vaccine resistant pathogens. The market focus is the treatment of the Human Immunodeficiency Virus (HIV), Hepatitis-C (HCV), and Biological Weapon candidates. Aethlon has an experienced management team, which receives support and guidance from globally recognized science advisors representing the infectious disease, biowarfare, and dialysis industries. Clinical trials to treat HIV and HCV patients in India are scheduled to begin in the coming months, and U.S. clinical studies are expected to begin later this year. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com.
Other notable stocks that look great lately from a fundamental and technical perspective include:
Merck & Co., Inc (NYSE:MRK): Bullish Bristol Myers Squibb Co (NYSE:BMY): Attractive Chiron Corporation (Nasdaq:CHIR): Bullish
About www.StockMarketNewsAlert.com
SMNA is an information and media investor relations firm that provides a Web-based forum for public and private issuers to communicate corporate news content to the business, financial and investing community through its Web site, located at http://www.stockmarketnewsalert.com
StockMarketNewsAlert.com's primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small- and micro-cap companies. Stockmarketnewsalert.com is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. SMNA's goal is to feature equity investments in micro- or small-capitalization companies that have the potential for long-term appreciation. SMNA provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. www.stockmarketnewsalert.com offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.stockmarketnewsalert.com
Let Stock Market News Alert help advertise for your company using our effective awareness campaigns. If you're interested in telling your story, we can help. Contact us at info@stockmarketnewsalert.com. SMNA's email alert service is free to those investors who sign up on the SMNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. To subscribe to this free service, visit the Stock Market News Alert home page at http://www.stockmarketnewsalert.com and select the "sign up" button. This profile is not without bias, and is a paid release. Information contained herein is the opinion of stockmarketnewsalert.com ("SMNA") and is intended to be used strictly for informational purposes. You should be aware that SMNA attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, SMNA does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of SMNA's analyses and/or parties related to those companies. SMNA also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
SMNA, because it relies on information supplied by various third parties, disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a SMNA analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an SMNA opinion, recommendation or analysis.
Information regarding companies which SMNA has an opinion upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company. You should be aware that SMNA is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating SMNA's statements regarding a company. This profile is not without bias, and is a paid release. First Equity Group, Inc. has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. FEG has been compensated Twenty one Thousand Dollars and twenty four thousand shares of 144 restricted stock for current coverage of Aethlon Medical, Inc. (OTCBB:AEMD), by the company, for services provided including dissemination of company information in this release. FEG's officers and directors reserve the right to buy shares of the companies discussed in this opinion and may profit in the event those shares rise in value. To date, zero shares have been sold. First Equity Group's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise in value. First Equity Group does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. To date, SMNA has sold zero shares of stock. SMNA's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When SMNA receives free trading shares as compensation for a profiled company, SMNA may sell part or all of any such shares during the period in which SMNA is performing such services.